Earnings summaries and quarterly performance for Corvus Pharmaceuticals.
Executive leadership at Corvus Pharmaceuticals.
Board of directors at Corvus Pharmaceuticals.
Research analysts who have asked questions during Corvus Pharmaceuticals earnings calls.
Aydin Huseynov
Ladenburg Thalmann
4 questions for CRVS
Also covers: ARDX, CAPR, CLRB +3 more
Jeff Jones
Oppenheimer & Co. Inc.
4 questions for CRVS
Also covers: ABEO, CLRB, CMMB +8 more
Graig Suvannavejh
Mizuho Securities
3 questions for CRVS
Also covers: ADAP, ADVM, ALEC +11 more
LW
Li Wang Watsek
Cantor Fitzgerald
3 questions for CRVS
Also covers: AFMD, ALXO, ARVN +7 more
JS
Jiale Song
Jefferies Financial Group Inc.
2 questions for CRVS
Also covers: ACRS, CTMX, CVAC +12 more
XL
Xun Lee
H.C. Wainwright & Co., LLC
2 questions for CRVS
Also covers: ATEC, CTSO, EDAP +2 more
CS
Craig Suvanevej
Mizuho Securities USA LLC
1 question for CRVS
RS
Roger Song
Jefferies
1 question for CRVS
Also covers: AADI, AKBA, ALT +13 more
Recent press releases and 8-K filings for CRVS.
Corvus Pharmaceuticals Commences Public Offering
CRVS
- Corvus Pharmaceuticals, Inc. has commenced an underwritten public offering of $150,000,000 of shares of its common stock and pre-funded warrants.
- The company expects to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of shares of common stock.
- Corvus Pharmaceuticals expects to use the net proceeds for working capital and general corporate purposes, including capital expenditures and research and development for its Phase 3 T cell lymphoma, and Phase 2 atopic dermatitis, hidradenitis suppurativa and asthma clinical trials.
- Jefferies and Goldman Sachs & Co. LLC are acting as lead book-running managers for the offering.
2 hours ago
Corvus Pharmaceuticals Presents Positive Phase I Clinical Trial Results for Soquelitinib in Atopic Dermatitis
CRVS
New Projects/Investments
- Corvus Pharmaceuticals presented positive results from its phase I clinical trial of Soquelitinib for atopic dermatitis, positioning it as a first-in-class oral drug.
- In Cohort 4, Soquelitinib achieved a mean percent reduction in EASI score of 72% at eight weeks (versus 40% for placebo, p-value 0.035), with 75% of patients achieving EASI 75.
- The drug demonstrated durable responses and efficacy in patients who had received prior systemic therapies, supported by a novel mechanism of action involving immune system rebalancing and Treg induction.
- Corvus plans to initiate a phase II randomized placebo-controlled trial in atopic dermatitis in Q1 2026, with additional phase II trials in hidradenitis suppurativa and asthma also planned for 2026, alongside an ongoing phase III trial in relapsed peripheral T-cell lymphoma.
- Soquelitinib is protected by composition of matter patents through 2042 and targets the atopic dermatitis market, which is projected to grow to $170 billion by 2030.
6 hours ago
Corvus Pharmaceuticals Presents Positive Phase 1 Results for Socalitinib in Atopic Dermatitis and Outlines Future Clinical Plans
CRVS
Product Launch
New Projects/Investments
- Corvus Pharmaceuticals announced positive results from its Phase 1 clinical trial of Socalitinib for atopic dermatitis, highlighting it as a potential first-in-class oral drug.
- In Cohort 4, 75% of patients achieved EASI 75, 25% achieved EASI 90, and 33% achieved IGA 0/1, with a mean EASI score reduction of 72% at eight weeks.
- Socalitinib demonstrated durable responses and comparable efficacy in patients with and without prior systemic therapies.
- The company plans to initiate a Phase 2 randomized placebo-controlled trial for Socalitinib in atopic dermatitis in Q1 2026, enrolling 200 patients, and also expects to start Phase 2 trials in hidradenitis suppurativa and asthma in 2026.
- An interim analysis from the ongoing Phase 3 lymphoma study is anticipated later in 2026.
8 hours ago
CRVS Presents Positive Phase I Clinical Trial Results for Socalitinib in Atopic Dermatitis
CRVS
New Projects/Investments
Product Launch
- Socalitinib's Phase I clinical trial for atopic dermatitis (AD) demonstrated positive results in Cohort 4, with 75% of patients achieving EASI 75, 25% achieving EASI 90, and 33% achieving IGA 0/1, alongside a mean percent reduction in EASI score of 72% at eight weeks of treatment.
- The drug appeared to be safe and effective, showing durable responses and no dose-limiting toxicities in prior studies, with a low adverse event rate in AD patients.
- Socalitinib was active in patients who had received prior systemic therapies, exhibiting similar efficacy in both systemic treatment-naive and experienced patients.
- The company plans to initiate a Phase 2 randomized placebo-controlled trial in AD in Q1 2026, enrolling 200 patients across four cohorts, and also has planned Phase 2 trials for hidradenitis suppurativa and asthma in 2026.
9 hours ago
Corvus Pharmaceuticals Announces Positive Soquelitinib Phase 1 Data for Atopic Dermatitis
CRVS
New Projects/Investments
- Corvus Pharmaceuticals announced positive results from Cohort 4 of its randomized, blinded, placebo-controlled Phase 1 clinical trial for soquelitinib in moderate to severe atopic dermatitis on January 20, 2026.
- The Cohort 4 data demonstrated favorable safety and efficacy, with 75% of soquelitinib patients achieving EASI 75, 25% achieving EASI 90, and 33% achieving IGA 0/1.
- The company plans to initiate a Phase 2 clinical trial for soquelitinib in patients with moderate to severe atopic dermatitis in the first quarter of 2026.
- No new safety signals were observed in Cohort 4, and all reported adverse events were Grade 1-2, not requiring dose modifications or interruptions.
11 hours ago
Corvus Pharmaceuticals Announces Positive Soquelitinib Phase 1 Clinical Trial Data for Atopic Dermatitis
CRVS
New Projects/Investments
- Corvus Pharmaceuticals announced positive results from cohort 4 of its randomized, blinded, placebo-controlled Phase 1 clinical trial for soquelitinib in patients with moderate to severe atopic dermatitis.
- The cohort 4 data demonstrated favorable safety and efficacy, with 75% of soquelitinib patients achieving EASI 75, 25% achieving EASI 90, and 33% achieving IGA 0/1, compared to 20%, 0%, and 0% for the placebo group, respectively. The mean percent reduction in EASI for soquelitinib patients in cohort 4 was 72% at day 56, compared to 40% for placebo patients.
- No new safety signals were observed as of January 15, 2026, with all reported adverse events being Grade 1-2 and not leading to dose modifications or interruptions.
- Based on these positive results, the company plans to initiate a Phase 2 clinical trial for soquelitinib in Q1 2026, enrolling approximately 200 patients with moderate-to-severe atopic dermatitis.
11 hours ago
Corvus Pharmaceuticals Presents Final Phase 1/1b Data for Soquelitinib in T Cell Lymphoma
CRVS
New Projects/Investments
- Corvus Pharmaceuticals presented final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma at the 67th American Society of Hematology Annual Meeting & Exposition.
- In the 200 mg BID cohort (N=24) of relapsed/refractory PTCL patients, the trial demonstrated a median progression-free survival of 6.2 months and a median overall survival of 28.1 months.
- This cohort also showed objective responses in 9 of 24 patients, including 6 complete responses, with no dose-limiting toxicities or significant adverse events observed.
- The data supports the ongoing registration Phase 3 trial for soquelitinib in relapsed/refractory PTCL, with interim data anticipated in late 2026 and trial completion in 2027.
- Soquelitinib has received Orphan Drug Designation for T cell lymphoma and Fast Track designation for relapsed/refractory PTCL from the FDA.
Dec 8, 2025, 3:30 PM
Corvus Pharmaceuticals Provides Update on Soquelitinib Development and Financial Runway
CRVS
New Projects/Investments
Guidance Update
- Corvus Pharmaceuticals (CRVS) is a clinical-stage company focused on developing first-in-class immune modulators, with its lead program, soquelitinib, in a Phase III registrational trial for peripheral T-cell lymphoma (PTCL) and a Phase Ib/soon-to-be Phase II trial for moderate to severe atopic dermatitis (AD).
- In atopic dermatitis, soquelitinib has demonstrated a safe profile and statistical separation from placebo at 28 days in initial cohorts, with a potential for a prolonged effect.
- The company is advancing soquelitinib into a global Phase II study for AD, a 12-week trial with an expected data readout in 2027.
- Corvus identifies a significant commercial opportunity in AD, estimating each 1% market share to be worth $1 billion, and plans to initiate an asthma study in 2026.
- As of September 30, Corvus reported $65 million in cash, providing a financial runway through Q4 2026.
Nov 10, 2025, 1:30 PM
Corvus Pharmaceuticals Reports Q3 2025 Financials and Soquelitinib Clinical Progress
CRVS
Earnings
New Projects/Investments
Board Change
- Corvus Pharmaceuticals reported a net loss of $10.2 million for the Third Quarter 2025, compared to a net loss of $40.2 million for the same period in 2024. Research and development expenses for Q3 2025 totaled $8.5 million, an increase from $5.2 million in Q3 2024.
- As of September 30, 2025, Corvus had $65.7 million in cash, cash equivalents, and marketable securities, and expects this cash to fund operations into the Fourth Quarter of 2026.
- For soquelitinib, results from the Extension Cohort 4 of the Phase I atopic dermatitis trial are anticipated to be reported in January 2026, and the Phase II atopic dermatitis trial is on track to begin in early Q1 2026.
- Enrollment is ongoing for the registrational Phase III trial of soquelitinib in relapsed Peripheral T-cell Lymphoma (PTCL), with interim data expected in late 2026.
- David Moore was appointed to the Board of Directors in October.
Nov 4, 2025, 9:30 PM
Corvus Pharmaceuticals Provides Business Update and Reports Q3 2025 Financial Results
CRVS
Earnings
Guidance Update
New Projects/Investments
- Corvus Pharmaceuticals reported a net loss of $10.2 million for the third quarter ended September 30, 2025, compared to a net loss of $40.2 million for the same period in 2024.
- Research and development expenses for Q3 2025 were $8.5 million, an increase from $5.2 million in Q3 2024, primarily due to higher clinical trial and manufacturing costs for soquelitinib.
- As of September 30, 2025, the company held $65.7 million in cash, cash equivalents, and marketable securities, and expects this cash to fund operations into the fourth quarter of 2026.
- The company completed enrollment in extension cohort 4 of the soquelitinib atopic dermatitis Phase 1 clinical trial, with data anticipated in January 2026, and is on track to initiate a Phase 2 clinical trial in early Q1 2026.
- Enrollment continues in the registrational Phase 3 clinical trial of soquelitinib in relapsed/refractory peripheral T cell lymphoma (PTCL), and final Phase 1/1b results for T cell lymphoma will be presented at the American Society of Hematology Annual Meeting in December 2025.
Nov 4, 2025, 9:01 PM
Quarterly earnings call transcripts for Corvus Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more